GlassScriptPhysician profile
Shalee O Nanney
NPI 1578088464
$5,176.45
in general payments reported to CMS, 2019-2025
31 companies · $1,159 in 2025
The $1,159 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $803 · 2022: $1,068 · 2023: $1,084 · 2024: $1,062 · 2025: $1,159.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,305.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,305.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,049.45 | 2021-2025 | |
| Pfizer INC. | $759.27 | 2021-2025 | |
| Novo Nordisk INC | $714.40 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $458.70 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $267.05 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $214.02 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $201.69 | 2024-2025 | Caplyta |
| Amgen INC. | $161.96 | 2021-2025 | Repatha, Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $155.65 | 2021-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $133.80 | 2021-2025 | Shingrix, Arexvy, Bexsero |
| Takeda Pharmaceuticals U.S.A., INC. | $103.92 | 2021-2022 | |
| Dexcom, INC. | $94.62 | 2021-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $91.64 | 2021-2025 | Jardiance |
| Axsome Therapeutics, INC. | $84.46 | 2024-2025 | Auvelity |
| Astrazeneca Pharmaceuticals LP | $80.99 | 2021-2024 | Farxiga, Breztri |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $74.00 | 2023-2025 | Gemtesa |
| Phathom Pharmaceuticals, INC. | $72.20 | 2024-2025 | Voquezna |
| Biohaven Pharmaceutical Holding Company LTD. | $60.79 | 2022 | |
| Exact Sciences Corporation | $50.66 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Biohaven Pharmaceuticals, INC. | $48.39 | 2021 | |
| Sanofi-Aventis U.S. LLC | $40.37 | 2021 | |
| Seqirus USA INC | $39.94 | 2024-2025 | Flucelvax, Fluad |
| Janssen Pharmaceuticals, INC | $39.17 | 2021 | |
| Merck Sharp & Dohme LLC | $38.70 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
| Corcept Therapeutics | $35.95 | 2025 | Korlym |
| Sunovion Pharmaceuticals INC. | $32.22 | 2022 | |
| Teleflex LLC | $15.96 | 2021 | |
| Amarin Pharma, INC. | $15.16 | 2021 | |
| Medtronic, INC. | $14.61 | 2024 | Intellis Adaptivestim |
| Kowa Pharmaceuticals America, INC. | $13.54 | 2025 | Zoryve |
| Intra-Sana Laboratories | $13.17 | 2024 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shalee Nanney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.